Parkinson’s disease is a neurodegenerative disease without any curative treatment or neuroprotective or disease-halting drugs. It is characterized by motor symptoms that are still quantified mostly by subjective methods. Studies have shown that combining surface electromyography (EMG) and kinematic measurements can lead to objective quantification of a patient’s neuromuscular and motor function.

A new study on wearable monitoring of negative myoclonus within the home environment is now available. The research was conducted in collaboration between the University of Eastern Finland, Kuopio University Hospital (KUH) - Kuopion yliopistollinen sairaala (KYS), UCL Queen Square Institute of Neurology and Adamant Health.

Meet us at the Neurologipäivät 2023 to learn more about our data-driven approach for managing Parkinson’s disease, and how it will help people with Parkinson’s to get the best treatment possible – improving their quality of life!

Adamant Health is participating in the 96. Kongress der Deutschen Gesellschaft für Neurologie taking place from 8 to 11 November 2023 in Berlin, Germany. Meet us at booth B17 to learn more about our data-driven approach for managing Parkinson’s disease!

We’ve just returned from this year’s International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen and are strongly encouraged by the valuable and in-depth discussions we had there. We feel it is absolutely key to continue educating the market about the EMG signal’s role in quantifying the neurophysiological basis of motor symptoms and why it provides a more accurate picture.

Adamant Health has developed a technology and service that will revolutionize the care of Parkinson's disease and other movement disorders. Business Kuopio has interviewed Adamant Health's founders Paulus Carpelan and Saara Rissanen.

Adamant Health is growing and entering a new phase in its journey, and we are looking for a Software Developer to strengthen our team. In this role you are developing mobile applications enabling our unique Parkinson’s disease measurement, connecting data to our cloud service, and communicating analyzed information back to the patient.

Adamant Health is participating in the International Congress of Parkinson's Disease and Movement Disorders taking place from 27 to 31 August 2023 in Copenhagen, Denmark. Meet us at booth C3-262 to learn more about our data-driven approach!

Adamant Health secures funding from Business Finland's Deep Tech Accelerator program for rapid market entry and targeted growth on international markets. The Deep Tech Accelerator funding will serve as a catalyst in accelerating Adamant Health's entry to selected European markets and drive our growth, particularly within our target customer segments.

Adamant Health’s project focusing on better understanding Parkinson’s disease patients’ lives at home is co-funded by the European Union.

After several successful recruitments during spring 2023, Adamant Health's team has been growing. Meet our team of 14 professionals dedicated to revolutionise the care of Parkinson's disease!

We are participating in the Liikehäiriöpäivät 2023, organised by the Finnish Neurological Society and the Finnish Movement Disorder Society, taking place from 4 - 5 May 2023 in Helsinki, Finland. Meet us at our stand or book a meeting to learn more about our technology and service, and how it can help you making better treatment decisions for your patients and improve their quality of life!

April marks Parkinson’s Awareness Month, an opportunity to increase awareness about the condition and a time to acknowledge the tremendous strength and resilience of people living with the disease and to celebrate the contributions of individuals and organizations supporting efforts to find effective treatments and improve the management Parkinson’s disease.

Adamant Health has opened an office at Hub Panostamo in KPY Novapolis, Kuopio.

Adamant Health participated with its growing team in the UEF Startup Day at the University of Eastern Finland on 19 January 2023.

Are you looking to put your professional expertise to good use by helping people suffering from severe chronic conditions to live a better life? Are you in your element at a fast-growing startup, where you have the opportunity to truly make a change? Do you wish to further develop healthcare systems to serve those in need? If this sounds like you, we’d love to hear from you!

The treatment of Parkinson’s disease is currently based on short doctor’s appointments arranged a few times per year, during which patients talk about their symptoms and the doctor makes observations on the patient. As the symptoms may vary from day to day, prescribing medications based on appointments alone is challenging.

Adamant Health Ltd is a health technology company founded in 2020 and it has its roots in medical physics research at the University of Eastern Finland. The company has developed a new measurement and analysis service to support evaluation of movement disorders, such as the symptoms of Parkinson’s disease and myoclonus-epilepsies. Neurocenter Finland has supported the product development.

Hyvä idea vaatii aina hyvän tiimin ja huippuosaamista. Idean lisäksi tarvitaan joku, joka osaa kaupallistaa idean myytävään muotoon. Adamant Health auttaa ratkaisemaan tämän hetken kriittisiä haasteita liittyen terveyteen, ja on juuri siksi yksi alueemme tulevia tähtiä, kiteyttää Business Kuopion yritysneuvoja Marja-Leena Laitinen.

Adamant Health teams up with German medtech company Gerresheimer to improve the care for people with Parkinson's disease.